Literature DB >> 10923926

Cytopathic effect of in situ gene therapy in prostate cancer.

G Ayala1, T M Wheeler, M Shalev, T C Thompson, B Miles, E Aguilar-Cordova, S Chakraborty, D Kadmon.   

Abstract

This is a morphologic study of in situ gene therapy effects in patients with prostate cancer using the Herpes Simplex VirusThymidine Kinase gene (HSV-tk) followed by ganciclovir. Prostatectomy specimens from the first 4 patients showed the following morphologic changes: (1) various degrees of necrosis were seen in cancer foci; (2) cytopathic changes were seen across the whole spectrum of Gleason grades; (3) the normal prostate was rarely affected by necrosis, but contained an intense mononuclear infiltrate; (4) loss of nuclear detail was a common finding. Volumetric studies showed that only portions of the tumor show morphologic effects as well as an inverse relationship between percentage of affected tumor and prostate and tumor size. An inflammatory response was observed, with predominance of CD20-positive cells in normal prostate tissue, CD8 (cytotoxic T cells) in the tumor, and macrophages in all areas of the treated prostates. We believe that these changes represent the cytopathic effect of our in situ gene therapy on prostate cancer, and that they trigger a local immune response.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10923926     DOI: 10.1053/hupa.2000.8453

Source DB:  PubMed          Journal:  Hum Pathol        ISSN: 0046-8177            Impact factor:   3.466


  5 in total

Review 1.  Gene therapy for prostate cancer.

Authors:  J R Gingrich; R D Chauhan; M S Steiner
Journal:  Curr Oncol Rep       Date:  2001-09       Impact factor: 5.075

2.  Study on the effect of BMSCs-EGFP-tk as mediator of HSV1-tk/GCV suicide gene therapy directed against A549 in vitro.

Authors:  Kun Yang; Wen-Gui Xu; Yong-Zhe Liu; Xiang-Rui Meng; Peng Chen; Li-Chuan Wu
Journal:  Int J Clin Exp Med       Date:  2014-09-15

3.  Enhanced central memory cluster of differentiation 8+ and tumor antigen-specific T cells in prostate cancer patients receiving repeated in situ adenovirus-mediated suicide gene therapy.

Authors:  Makoto Kubo; Takefumi Satoh; Ken-Ichi Tabata; Hideyasu Tsumura; Masatsugu Iwamura; Shiro Baba; Timothy C Thompson; Fumiya Obata
Journal:  Mol Clin Oncol       Date:  2015-02-26

4.  Cytopathic effects and local immune responses in repeated neoadjuvant HSV-tk + ganciclovir gene therapy for prostate cancer.

Authors:  Nobuyuki Yanagisawa; Takefumi Satoh; Ken-Ichi Tabata; Hideyasu Tsumura; Yasutomo Nasu; Masami Watanabe; Timothy C Thompson; Isao Okayasu; Yoshiki Murakumo; Shiro Baba; Masatsugu Iwamura
Journal:  Asian J Urol       Date:  2020-06-16

Review 5.  Gene therapy for prostate cancer.

Authors:  J R Gingrich; R D Chauhan; M S Steiner
Journal:  Curr Urol Rep       Date:  2001-06       Impact factor: 2.862

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.